ABSTRACT
INTRODUCTION
The Ras/Raf-1/mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) pathway is a highly conserved signaling cascade that regulates multiple biological processes, including mitogenesis and differentiation (1, 2) . Many different growth factor receptors are able to activate the small G protein Ras, which as a consequence binds the Raf-1 kinase and thereby recruits Raf-1 to the inner surface of the cell membrane. After its activation, Raf-1 phosphorylates and activates the mitogen-activated protein kinase kinase, MEK, which in turn phosphorylates and activates the mitogen-activated protein kinase, ERK. Phosphorylated ERK is able to translocate into the nucleus and regulate gene expression via activation of various transcription factors (3, 4) .
It has been shown that the Ras signaling pathway is constitutively active in a great number of malignant melanomas (5) . Recently, it was shown that mutations primarily occur in the BRCA2-associated factor (BRAF) gene (6, 7) . Indeed, Pollock et al. (7) observed mutations in the BRAF gene not only in samples of malignant melanoma, but also in nevi, suggesting that the BRAF mutation is an early but not sufficient event in malignant melanocyte transformation. Other molecules that regulate the Ras pathway are expected to play important roles in the control of this signaling cascade.
One inhibitory molecule that down-regulates the effects of the Ras/Raf/MEK/ERK signaling pathway is the Raf kinase inhibitor protein (RKIP). RKIP directly interacts with Raf-1 and MEK. It dissipates the Raf-1/MEK interaction, thereby preventing the activation of MEK by Raf-1 and downstream signal transduction (8, 9) . Interestingly, RKIP was found to be a member of the phosphatidylethanolamine-binding protein family, a ubiquitously expressed and evolutionarily conserved group of proteins (10) .
The aim of this study was to analyze the role of RKIP in malignant melanoma. RKIP expression has recently been shown to be downregulated in metastatic prostate cancers, and the loss of RKIP levels was suggested to promote the metastatic potential of prostate cancer cells (11) . Therefore, we were interested to investigate the role of RKIP in malignant melanoma, a cancer notorious for its capacious potential to metastasize.
MATERIALS AND METHODS

Cell Lines and Culture Conditions. The melanoma cell lines Mel Im, Mel
Ei, Mel Wei, Mel Ho, Mel Juso, Mel Ju, SK Mel 28, HMB2, and HTZ19d have been described in detail previously (12, 13) . The cell lines Mel Ei, Mel Wei, Mel Ho, and Mel Juso were derived from a primary cutaneous melanoma, and Mel Im, Mel Ju, SK Mel 28, HMB2, and HTZ19d were derived from metastases of malignant melanomas. For tissue culture, the cells were maintained in DMEM supplemented with penicillin (400 units/ml), streptomycin (50 g/ml), L-glutamine (300 g/ml), and 10% FCS (Sigma, Deisenhofen, Germany) and split 1:5 every 3 days.
Human primary melanocytes derived from normal skin were cultivated in melanocyte medium MGM-3 (Life Technologies, Eggenstein, Germany) in a humidified atmosphere of 5% CO 2 at 37°C. Cells were used at passages 6 -10 and not later than 3 days after passaging. Cells were detached for propagation or assay with 0.05% trypsin and 0.04% EDTA in PBS.
For demethylation assays the cells were treated for 24 or 48 h with 5-azacytidine (Sigma) at a final concentration of 10 M (14, 15) .
Stable Transfection of Melanoma Cells with RKIP Expression Plasmid. A panel of Mel Im cell clones showing overexpression of RKIP was established by stable transfection with RKIP-sense expression plasmid (RKIP full-length coding sequence cloned into pcDNA3.1 (Invitrogen NV, Leek, Holland)). Controls received pcDNA3.1 alone. Transfections were performed using the LipofectAMINE plus method (Life Technologies). One day after transfection, cells were placed into selection medium containing 1 mg/ml Geneticin (Sigma). After 25 days of selection, individual Geneticin-resistant colonies were subcloned. The amount of RKIP expression in these clones was determined by reverse transcription-PCR and Western blot analysis.
Assays for Cell Function. Proliferation, migration, and invasion of the stably transfected, RKIP re-expressing melanoma cell clones were measured as described previously (16) .
Invasion assays were performed in Boyden chambers containing polycarbonate filters with an 8-m pore size. In brief, filters were coated with a commercially available reconstituted basement membrane (Matrigel; Becton Dickinson, Heidelberg, Germany), and the lower compartment was filled with endothelial-cell-conditioned medium as chemoattractant. Mel Im cells and Mel Im RKIP cell clones were harvested by trypsinization, resuspended in DMEM without FCS at a density of 2 ϫ 10 5 cells/ml, and placed in the upper compartment of the chambers. After incubation for 4 h at 37°C, the filters were removed. The cells adhering to the lower surface were fixed, stained, and counted. Fifteen random fields were counted at 200-fold magnification. Each sample was assayed in triplicate, and all experiments were repeated three times.
RNA Isolation and Reverse Transcription. For reverse transcription-PCR total cellular RNA was isolated from cultured cells using the RNeasy kit (Qiagen, Hilden, Germany). The integrity of the RNA was controlled on 1% agarose/formaldehyde gel, and subsequently, cDNAs were generated by reverse transcriptase reactions. The reverse transcription reaction was performed in a 20-l reaction volume containing 2 g of total cellular RNA, 4 l of 5ϫ first-strand buffer (Life Technologies), 2 l of 0.1 M DTT, 1 l of dN 6 primer (10 mM), 1 l of dNTPs (10 mM), and diethyl pyrocarbonate water. The reaction mix was incubated for 10 min at 70°C. Then 1 l of Superscript II reverse transcriptase (Life Technologies) was added, and RNAs were transcribed for 1 h at 37°C. Subsequently, reverse transcriptase was inactivated at 70°C for 10 min, and RNA was degraded by digestion with 1 l of RNase A (10 mg/ml) at 37°C for 30 min. cDNAs were controlled by PCR amplification of ␤-actin.
RKIP-RNA Mutational Analysis. The complete coding region of RKIP was amplified by reverse transcription-PCR from cDNA using specific primers (RKIP108for, ATGCCGGTGGACCTCAGC; RKIP657rev, GCTGCTCGTA-CAGTTTGGGC), resulting in a 546-bp fragment. The PCR reaction was performed in a 50-l reaction volume containing 5 l of 10ϫ Taq buffer, 1 l of cDNA, 0.5 l of each primer (0.2 M), 0.5 l of dNTPs (10 mM), 0.5 l of Taq polymerase (5 units/l), and 41 l of water. The amplification reactions were performed by 35 repetitive cycles of denaturing for 1 min at 94°C, annealing for 1 min at 58°C, extension for 1 min at 72°C, and a final extension step at 72°C for 5 min. The PCR products were resolved on 1% agarose gels. For sequencing, the products were purified by polyethylene glycol precipitation to remove unincorporated primers and dNTPs. Both strands were sequenced for each PCR product from at least two independent PCR reactions. Sequences were compared with the gene data bank by means of BLAST search (National Center of Biotechnology Information).
Analysis of RKIP Expression by Quantitative PCR. Quantitative real time-PCR was performed on a Lightcycler (Roche, Mannheim, Germany). Two l of cDNA template, 1.6 l of 25 mM MgCl 2 , 0.2 M forward and reverse primers (RKIPfor455, CCTCCACCGCTATGTCTGGC; RKIP657rev, GCTGCTCGTACAGTTTGGGC), and 2 l of SybrGreen LightCycler Mix in a total of 20 l were applied to the following PCR program: 30 s 95°C (initial denaturation); 20°C/s temperature transition rate up to 95°C for 15 s, 64°C for 3 s, 72°C for 5 s; 85°C acquisition mode single; repeated for 40 times (amplification). The PCR product was evaluated by melting curve analysis following the manufacturer's instructions and by checking the PCR products on 1.8% agarose gels. All quantitative PCR experiments were repeated six times.
Protein Analysis in Vitro (Western Blotting). For protein isolation, 2 ϫ 10 6 cells were washed in 1ϫ PBS and lysed in 200 l of radioimmunoprecipitation assay buffer (Roche). The protein concentration was determined using the BCA protein assay reagent (Pierce). Equal amounts of cellular protein were denatured at 70°C for 10 min after addition of Rotiload buffer (Roth, Karlsruhe, Germany) and subsequently separated on NuPage-SDS-gels (Invitrogen, Groningen, the Netherlands). Forty g of total protein were loaded for Western blots with stably transfected cell lines, and 20 g of total protein were used for Western blots with the diverse melanoma cell lines. After transferring the proteins onto polyvinylidene difluoride membranes (Bio-Rad, Hercules, CA), the membranes were blocked in 3% BSA/PBS for 1 h and incubated with a 1:1500 dilution of primary polyclonal rabbit anti-RKIP antibody (9) overnight at 4°C. For detection of phospho-MEK (pMEK), polyclonal rabbit anti-pMEK antibody (Cell Signaling) in a dilution of 1:2000 was used; phospho-ERK (pERK) was detected with a monoclonal anti-phospho p42/44 antibody (Cell Signaling, Beverly, MA) in a 1:2000 dilution; and ERK levels were detected with an anti-p42/44 polyclonal rabbit antibody (1:1000). A 1:1500 dilution of anti-IgG-AP (Sigma) was used as secondary antibody. Staining was performed using 5-bromo-4-chloro-3-indolyl phosphate/nitroblue tetrazolium tablets (Sigma). All Western blot experiments were repeated at least four times, and pMEK Western blots were repeated two times.
Immunohistochemistry. Paraffin-embedded tissue sections from patients with benign melanocytic nevi, malignant melanomas, and melanoma metastases were screened for RKIP protein expression by immunohistochemistry. The tissues were deparaffinated, rehydrated, and subsequently incubated with primary polyclonal rabbit RKIP antibody (1:1500) overnight at 4°C. The secondary antibody (biotin-labeled antirabbit; 1:1000; Immuno Research) was incubated for 30 min at room temperature, followed by incubation with streptavidin-POD (DAKO, Hamburg, Germany) for 30 min. Antibody binding was visualized using 3-amino-9-ethylcarbazol (AEC) solution (DAKO). Finally, the tissues were counterstained by hemalaun.
Transfection Experiments. For transient transfections, 2 ϫ 10 5 cells/well were seeded into 6-well plates and transiently transfected with 0.5 g of pAP-1 luc plasmid (Stratagene, La Jolla, CA) using the LipofectAMINE Plus method (Life Technologies) according to the manufacturer's instructions. Twenty-four h after transfection, the cells were lysed, and the luciferase activity in the lysate was measured. To normalize transfection efficiency, 0.2 g of a pRL-TK plasmid (Promega, Mannheim, Germany) was cotransfected, and renilla luciferase activity was measured by a luminometric assay (Promega). All transfection experiments were repeated three times.
Statistical Analyses. Student's unpaired test was used to test differences in the expression. Two-tailed statistical tests are used throughout; P Ͻ 0.05 was considered to be statistically significant ‫,ء(‬ P Ͻ 0.05; ‫,ءء‬ P Ͻ 0.01; and ‫,ءءء‬ P Ͻ 0.001). All statistical analyses were performed using the Prism 2.01 software (GraphPad Inc., San Diego, CA). All indicated error bars represent SD.
RESULTS
It is well established that the ERK is constitutively hyperactivated in the majority of malignant melanomas and may contribute to the pathogenesis of this tumor. In many cases, ERK hyperactivation can be explained by activating mutations occurring in upstream activators of ERK, such as Ras or Raf. Indeed, activating mutations in N-Ras or BRAF are found in up to 15 or 66% of melanomas, respectively (3). However, ERK hyperactivation is still observed in melanomas that do Analysis for Mutations in RKIP RNA. All nine human melanoma cell lines were evaluated for mutations in the RKIP mRNA and compared with normal human epidermal melanocytes (NHEM). The complete RKIP-coding region was amplified by reverse transcription-PCR. All cell lines examined expressed RKIP mRNA at the expected length, indicating that no deletions or mutational insertions had occurred (Fig. 1) . As a control, the RKIP coding sequence was amplified with NHEM cDNA as template. The same cDNAs were used to amplify ␤-actin as a control for the integrity of the cDNA.
The PCR products were purified and subsequently sequenced using two different primers. The analysis of all sequenced PCR products did not reveal any sequence variation within the coding region of the RKIP gene locus (data not shown). Hence, RKIP does not seem to be mutated in melanomas, at least not in the small number of samples in this study.
Expression of RKIP in Melanoma Cell Lines. The entire panel of nine human melanoma cell lines was further evaluated for levels of RKIP mRNA expression using quantitative reverse transcription-PCR and compared with melanocytes (NHEM). Obvious and reproducible down-regulation of RKIP expression was found in all melanoma cell Fig. 3 . Western blot analyses of RKIP and pERK1/2 protein expression in melanoma cell lines. A, in eight of nine melanoma cell lines, the expression of RKIP was reduced in comparison with NHEM; in seven cell lines, this reduction was shown to be significant (P Ͻ 0.05). As loading control, the blot was reprobed with an anti-␤-actin antibody. B, pMEK1/2 levels and pERK1/2 levels in relation to ERK1/2 protein levels revealed higher activity of ERK1/2 in all melanoma cell lines, although significantly increased pERK1/2 levels were only detected in four of nine cell lines (P Ͻ 0.05). The blots shown in A and B are representative examples. The experiments were repeated four times, and the blots were quantified by laser densitometry. The compiled quantification results of four independent experiments are represented in the graphs. The levels of pERK are normalized to the levels of total ERK in each cell line. Error bars indicate SD. (Fig. 2, f) .
Because this reduction in mRNA expression could not be explained by loss or mutation of the RKIP gene in the melanoma cell lines, we hypothesized that promoter hypermethylation could have silenced gene expression. To test this hypothesis, all cell lines were exposed to the demethylating agent 5-azacytidine, and RKIP mRNA expression was quantified by reverse transcription-PCR. Our results clearly show that 5-azacytidine treatment did not significantly induce RKIP expression. Therefore, we conclude that promoter hypermethylation is not the cause of down-regulation of RKIP mRNA expression in the melanoma cell lines in comparison with NHEM (Fig. 2, u) .
These results clearly indicate that promoter hypermethylation is not responsible for down-regulation of RKIP in melanoma cell lines, but they implicate a transcriptional control of RKIP expression in the different melanoma cell lines.
RKIP Protein Expression in Melanoma Cell Lines. Next, the nine different melanoma cell lines were screened for RKIP protein expression by Western blotting using an anti-RKIP antibody (Fig.  3A) . Consistent with the reduced amount of mRNA expression, only weak levels of RKIP protein were detected in all of the melanoma cell lines except of Mel Wei compared with NHEM. For Mel Ho cells, down-regulation was obvious and reproducible and almost reached significance (P ϭ 0.0518). Relative to ␤-actin as loading control, densitometric quantification of RKIP levels revealed significant down-regulation in the melanoma cell lines in comparison with RKIP protein levels in NHEM. The results are consistent with the data obtained from the quantitative reverse transcription-PCR except for SK Mel 28 cells, which feature a similar expression of RKIP mRNA but express significantly less RKIP protein compared with NHEM. These data suggest that RKIP expression is primarily regulated at the transcriptional level, although posttranscriptional mechanisms seem to be used by some cells such as SK Mel 28.
Activation of MEK in the melanoma cell lines was shown by probing Western blots with a phospho-specific anti-MEK antibody, and activation of ERK1/2 in the melanoma cell lines was analyzed by probing Western blots with a phospho-specific anti-ERK antibody. Fig. 4 . Immunostaining of RKIP in human melanocytic tumors. Tissue sections were immunostained with RKIP antibody and developed in red so that the RKIP stain could be distinguished from the brown melanin pigment. Slides were counterstained with hemalaun and photographed at ϫ200 magnification except A, which was photographed at ϫ100 and E at ϫ50. Scale bars indicate 100 m. A, section of normal skin. Epidermis and endothelia of blood vessels and capillaries are positively stained for RKIP expression. B, strong cytoplasmatic RKIP staining in benign melanocytic nevi (marked by black arrows). C and D, focally positive (black arrows) and negative RKIP staining (arrowhead) in primary cutaneous melanomas. E and F, negative or weak staining pattern in metastases from cutaneous melanomas. Small round cells underneath the metastatic infiltrate represent resident lymphocytes of the lymph node (white arrows).
DOWN-REGULATION OF RKIP IN MELANOMA METASTASIS
Research. We observed a consistently stronger activity of MEK1/2 and ERK1/2 in all nine cell lines in comparison with NHEM (Fig. 3B) , although significantly higher pERK1/2 levels could only be shown in four of nine cell lines.
Analysis of RKIP Protein Expression in Vivo. To examine RKIP expression in vivo, 15 tissue samples from patients with benign melanocytic nevi, primary malignant melanomas, and metastatic malignant melanomas were immunostained with RKIP antibody. Representative sections are presented in Fig. 4 . The intensity of RKIPpositive cells was reduced in primary malignant melanomas compared with nevi. In metastatic lesions, an additional reduction of expression was seen with cells revealing only very weak staining or no RKIP staining at all.
In summary, these data show an inverse correlation between RKIP protein expression and tumor progression as the amount of RKIP protein staining decreased from benign melanocytic nevi to primary melanomas and even further from primary melanomas to metastatic melanomas in vivo.
Functional Relevance of Loss of RKIP Expression.
To analyze the functional role of RKIP in melanoma cells, we overexpressed RKIP in the melanoma cell line Mel Im by stable transfection with an RKIP expression construct. Successful overexpression of RKIP in the cell clones (Mel Im RKIP1 and 4) was shown by quantitative reverse transcription-PCR (Fig. 5A ) and Western blotting (Fig. 5, B and C) , whereas no changes of RKIP expression were seen in two controltransfected cell clones (Mel Im pcDNA 5 and 7). (Fig. 5B ). Additionally, we tested the activation of an activator protein 1 (AP-1) reporter construct in control and RKIP stably transfected cell lines using luciferase reporter gene assays. We observed a strongly reduced activity of the AP-1 reporter in RKIP-overexpressing cell lines in comparison with control cell lines ( To study the functional relevance of RKIP expression, two different assays were performed. Proliferation assays revealed no changes in proliferation comparing the RKIP-expressing cell clones to the controls and untransfected Mel Im cells. The respective doubling times were: Mel Im, 1.69 Ϯ 0.027 days; Mel Im pcDNA5, 1.78 Ϯ 0.039 days; Mel Im pcDNA7, 1.61 Ϯ 0.045 days; Mel Im RKIP1, 1.82 Ϯ 0.059 days; Mel Im RKIP4, 1.49 Ϯ 0.12 days. Interestingly however, invasion assays using the Boyden Chamber system showed a strong reduction of invasive potential in the RKIP re-expressing cell clones (Fig. 6) . Mel Im and control Mel Im pcDNA5 and 7 clones did not show significant changes in invasiveness, whereas RKIP-transfected cell clones Mel Im RKIP1 and Mel Im RKIP4 displayed significantly reduced invasiveness in comparison with the controls.
DISCUSSION
The Ras/Raf/MEK/ERK signaling cascade is known to be an important pathway that regulates various cellular responses to extracellular signals. It has been shown before that mutations of several different proteins of this cascade can lead to malignant transformation of melanocytes: activating mutations in the small G protein Ras are found in 25% of all cancers and in 9 -15% of melanomas (6, (17) (18) (19) . Mutations of BRAF have been observed in 60 -66% of malignant melanomas by Davies et al. (6) . Notably, however, in subsequent studies, similar mutations were detected in 82% of nevi (7), which typically do not feature constitutive ERK, suggesting that mutations in BRAF are not sufficient to cause constitutive activation of the Ras/ Raf/MEK/ERK signaling pathway.
Dong et al. (20) suggest that mutations in the BRAF gene correlate with progression rather than initiation of human melanoma. In fact, activation of ERK is low in atypical nevi but becomes readily detectable in radial growth melanoma and more progressed tumors (21) . Further activating mutations in the ERK pathway are known for MEK (22, 23) . Although MEK mutations have not yet been found in tumors, activated MEK mutants induce cellular transformation and invasiveness in NIH 3T3 cells and in a rodent tumor model (24, 25) . An influence of MEK mutations in transformation of melanocytes has also been suggested by Govindarajan et al. (26) , who showed that the expression of activated MEK mutants in immortalized melanocytes conveys them with the ability to form tumors in mice.
In this study, we have investigated the role of RKIP in progression of malignant melanoma. Fu et al. (11) have analyzed the expression of RKIP in prostate cancer and found that RKIP is expressed in primary prostate tumors but down-regulated in metastases. They further showed that the overexpression of RKIP in a metastatic prostate cancer cell line did not affect its growth rate in vitro but reduced its metastatic potential in an orthotopic mouse model. However, no previous studies on RKIP regulation in other cancers, including malignant melanomas, have been reported thus far.
Our study revealed no loss of the RKIP genomic region in any of the nine analyzed melanoma cell lines as reverse transcription-PCR of different regions spanning the entire RKIP-coding sequence revealed products at the expected lengths. Sequencing revealed no mutations in the coding region of RKIP in any of the analyzed cell lines. Additionally, alterations of the genomic region of RKIP on human chromosome 12q23 and its adjacent areas have not been reported thus far for any cancer entities, contributing to our hypothesis that not chromosomal changes but other alterations lead to dysregulation of RKIP.
Quantification of mRNA expression by real-time PCR showed a marked down-regulation of RKIP expression in seven of nine analyzed melanoma cell lines. Additional experiments revealed that this down-regulation was not due to promoter hypermethylation, because it could not be reversed after demethylation by treatment of the cells with 5-azacytidine. In Mel Wei and SK Mel 28 cells, we did not see down-regulation of RKIP expression but still increased levels of activated ERK1/2. Therefore, we speculate that these cell lines might harbor an activating mutation in the Ras signaling cascade downstream of Raf. For this reason, we are currently investigating the mutational status of MEK in these cell lines, because it has been reported that constitutive activation of MEK is able to induce malignant transformation of melanocytes (26) . Importantly, in a mouse model of melanoma, a pharmacological MEK inhibitor could interfere with the formation of lung metastases and even cause regression of established metastases (27) .
By immunostaining of melanocytic tumors, an obvious downregulation of RKIP expression was found that correlated with malignant tumor progression. In nevi, almost all samples showed strong RKIP expression, whereas RKIP expression was diminished or completely lost in primary malignant melanoma and in metastases.
Stably transfected, RKIP-overexpressing Mel Im cells exhibited decreased MEK 1/2 and ERK1/2 activity and decreased AP-1 reporter gene activity compared with control cells. These data confirm the original function of RKIP as an inhibitor of Raf/MEK/ERK-mediated signaling (8, 9) .
Analyzing the functional relevance of RKIP, we tested the effect of RKIP overexpression on tumor cell migration and invasion. Here, we could clearly show that melanoma cells overexpressing RKIP revealed strong reduction in their invasive potential. Comparable results were obtained by Fu et al. (11) in prostate cancer cell lines, in which loss of RKIP expression has been reported and was correlated to the metastatic potential in a rodent tumor model. Additionally, we could show that RKIP has no influence in vitro on melanoma cell proliferation, a finding that was also reported for prostate cancer cell lines (11) .
Taken together, our results suggest that the reduction of RKIP levels in malignant melanoma contributes to the constitutive activation of the Ras signaling cascade and is conducive to the metastatic potential of melanoma cells. 
